Citius Pharmaceuticals, Inc. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
Citius Pharmaceuticals, Inc. (CTXR) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $7.77 million as of 2025-09-30, per its 10-K filed 2025-12-23.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2025-12-23
- 2025-09-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $7.77M.
- 2024-09-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $6.71M.
- 2023-09-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $6.14M; Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs as first filed $3.64M.
- 2022-09-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $5.56M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs as first filed |
|---|---|---|
| 2025-09-30 | $7.77M 10-K · filed 2025-12-23 | |
| 2024-09-30 | $6.71M 10-K · filed 2025-12-23 | |
| 2023-09-30 | $6.14M 10-K · filed 2024-12-27 | $3.64M 10-K · filed 2023-12-29 |
| 2022-09-30 | $5.56M 10-K · filed 2022-12-22 | |
| 2021-09-30 | $4.99M 10-K · filed 2022-12-22 | |
| 2020-09-30 | $4.99M 10-K · filed 2021-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |